Improving HbA1c levels with advanced hybrid closed-loop therapy
- PMID: 36058209
- DOI: 10.1016/S2213-8587(22)00245-5
Improving HbA1c levels with advanced hybrid closed-loop therapy
Conflict of interest statement
PGJ has received travel honorarium and research support from Dexcom; has received research support and licensing revenue from Agamatrix; and is a co-founder and owns stock in Pacific Diabetes Technologies.
Comment on
-
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.Lancet Diabetes Endocrinol. 2022 Oct;10(10):720-731. doi: 10.1016/S2213-8587(22)00212-1. Epub 2022 Sep 1. Lancet Diabetes Endocrinol. 2022. PMID: 36058207 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
